Zevra Therapeutics Inc (NASDAQ: ZVRA)’s stock price has increased by 3.98 compared to its previous closing price of 7.53. However, the company has seen a 5.95% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-06 that New clinical efficacy and safety data for arimoclomol as a possible treatment for Niemann-Pick disease type C, including from long-term and real-world settings, demonstrate clinically meaningful reduction in disease progression
Is It Worth Investing in Zevra Therapeutics Inc (NASDAQ: ZVRA) Right Now?
Company’s 36-month beta value is 1.95.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ZVRA is 52.29M, and currently, short sellers hold a 7.33% ratio of that floaft. The average trading volume of ZVRA on September 19, 2024 was 829.28K shares.
ZVRA’s Market Performance
ZVRA’s stock has seen a 5.95% increase for the week, with a 10.59% rise in the past month and a 72.09% gain in the past quarter. The volatility ratio for the week is 6.98%, and the volatility levels for the past 30 days are at 5.94% for Zevra Therapeutics Inc The simple moving average for the past 20 days is 5.98% for ZVRA’s stock, with a 36.92% simple moving average for the past 200 days.
Analysts’ Opinion of ZVRA
Many brokerage firms have already submitted their reports for ZVRA stocks, with Maxim Group repeating the rating for ZVRA by listing it as a “Buy.” The predicted price for ZVRA in the upcoming period, according to Maxim Group is $18 based on the research report published on April 02, 2024 of the current year 2024.
Maxim Group gave a rating of “Buy” to ZVRA, setting the target price at $12 in the report published on March 17th of the previous year.
ZVRA Trading at 14.58% from the 50-Day Moving Average
After a stumble in the market that brought ZVRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.23% of loss for the given period.
Volatility was left at 5.94%, however, over the last 30 days, the volatility rate increased by 6.98%, as shares surge +3.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +74.39% upper at present.
During the last 5 trading sessions, ZVRA rose by +5.95%, which changed the moving average for the period of 200-days by +60.78% in comparison to the 20-day moving average, which settled at $7.40. In addition, Zevra Therapeutics Inc saw 19.54% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZVRA starting from Clifton R. LaDuane, who purchase 2,000 shares at the price of $6.77 back on Jul 17 ’24. After this action, Clifton R. LaDuane now owns 18,469 shares of Zevra Therapeutics Inc, valued at $13,540 using the latest closing price.
Anderson Thomas, the Director of Zevra Therapeutics Inc, purchase 10,000 shares at $6.81 during a trade that took place back on Jul 16 ’24, which means that Anderson Thomas is holding 20,000 shares at $68,065 based on the most recent closing price.
Stock Fundamentals for ZVRA
Current profitability levels for the company are sitting at:
- -3.1 for the present operating margin
- 0.46 for the gross margin
The net margin for Zevra Therapeutics Inc stands at -2.74. The total capital return value is set at -0.65. Equity return is now at value -130.22, with -52.61 for asset returns.
Based on Zevra Therapeutics Inc (ZVRA), the company’s capital structure generated 0.64 points at debt to capital in total, while cash flow to debt ratio is standing at -0.95. The debt to equity ratio resting at 1.81. The interest coverage ratio of the stock is -18.73.
Currently, EBITDA for the company is -48.6 million with net debt to EBITDA at -0.29. When we switch over and look at the enterprise to sales, we see a ratio of 18.02. The receivables turnover for the company is 2.68for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.00.
Conclusion
In a nutshell, Zevra Therapeutics Inc (ZVRA) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
